255 related articles for article (PubMed ID: 11740804)
1. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
George D
Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
[TBL] [Abstract][Full Text] [Related]
2. Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
George D
Adv Exp Med Biol; 2003; 532():141-51. PubMed ID: 12908555
[TBL] [Abstract][Full Text] [Related]
3. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
[TBL] [Abstract][Full Text] [Related]
4. The biology of signal transduction inhibition: basic science to novel therapies.
Griffin J
Semin Oncol; 2001 Oct; 28(5 Suppl 17):3-8. PubMed ID: 11740801
[TBL] [Abstract][Full Text] [Related]
5. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
Bran B; Bran G; Hörmann K; Riedel F
Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
[TBL] [Abstract][Full Text] [Related]
6. [Imatinib].
Urabe A
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
8. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
9. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
10. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy.
Savikko J; Taskinen E; Von Willebrand E
Transplantation; 2003 Apr; 75(8):1147-53. PubMed ID: 12717194
[TBL] [Abstract][Full Text] [Related]
11. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Pietras K; Rubin K; Sjöblom T; Buchdunger E; Sjöquist M; Heldin CH; Ostman A
Cancer Res; 2002 Oct; 62(19):5476-84. PubMed ID: 12359756
[TBL] [Abstract][Full Text] [Related]
13. Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.
Kindler HL
Lung Cancer; 2004 Aug; 45 Suppl 1():S125-7. PubMed ID: 15261445
[TBL] [Abstract][Full Text] [Related]
14. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
Holdhoff M; Kreuzer KA; Appelt C; Scholz R; Na IK; Hildebrandt B; Riess H; Jordan A; Schmidt CA; Van Etten RA; Dörken B; le Coutre P
Blood Cells Mol Dis; 2005; 34(2):181-5. PubMed ID: 15727903
[TBL] [Abstract][Full Text] [Related]
16. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits.
Leppänen O; Rutanen J; Hiltunen MO; Rissanen TT; Turunen MP; Sjöblom T; Brüggen J; Bäckström G; Carlsson M; Buchdunger E; Bergqvist D; Alitalo K; Heldin CH; Ostman A; Ylä-Herttuala S
Circulation; 2004 Mar; 109(9):1140-6. PubMed ID: 14769706
[TBL] [Abstract][Full Text] [Related]
17. Signal transduction inhibition: changing paradigms in cancer care.
Schiffer CA
Semin Oncol; 2001 Oct; 28(5 Suppl 17):34-9. PubMed ID: 11740805
[TBL] [Abstract][Full Text] [Related]
18. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
Campbell JS; Johnson MM; Bauer RL; Hudkins KL; Gilbertson DG; Riehle KJ; Yeh MM; Alpers CE; Fausto N
Differentiation; 2007 Nov; 75(9):843-52. PubMed ID: 17999742
[TBL] [Abstract][Full Text] [Related]
19. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor.
Rosenberg A; Mathew P
Expert Opin Investig Drugs; 2013 Jun; 22(6):787-94. PubMed ID: 23540855
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
Sjöblom T; Shimizu A; O'Brien KP; Pietras K; Dal Cin P; Buchdunger E; Dumanski JP; Ostman A; Heldin CH
Cancer Res; 2001 Aug; 61(15):5778-83. PubMed ID: 11479215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
